glp 1 gip glucagon triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism The clinically most relevant mechanisms
Description
JIR (2018) 11:95109
60 Research has extensively examined the combined agonists of GLP-1 and GIP1-RA for their potential impact on diabetes management and weight reduction
J Neurosci (2012) 32:481220
3.10 Renal effects Exenatide has been associated with the development of acute kidney injury in about 100 case reports [140-146]
